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Most of the colorectal cancer (CRC) cases are sporadic, only 25% of the patients have a family history of the disease, and major
genes causing syndromes predisposing to CRC onlyaccount for 5-6% ofthe total cases.The followingsubtypes canbe recognized:
MIN (microsatellite instability), CIN (chromosomal instability), and CIMP (CpG island methylator phenotype). CIN occurs in
80–85% of CRC. Chromosomal instability proceeds through two major mechanisms, missegregation that results in aneuploidy
through the gain or loss of whole chromosomes, and unbalanced structural rearrangements that lead to the loss and/or gain of
chromosomal regions. The loss of heterozygosity that occur in the ﬁrst phases of the CRC cancerogenesis (in particular for the
genes on 18q) as well as the alteration of methylation pattern of multiple key genes can drive the development of colorectal cancer
by facilitating the acquisition of multiple tumor-associated mutations and the instability phenotype.
1.Introduction
Worldwide, more than one million individuals develop
colorectal cancer (CRC) each year, and the disease-speciﬁc
mortality rate is nearly 33% in the developed world [1].
In Europe cancer of the gastrointestinal tract is the most
common cancer: more than half of gastrointestinal cancer
cases arise from the colon and around 250,000 new colon
cases are diagnosed every year, accounting for around 9% of
all the malignancies [2]. Colorectal cancer most commonly
occurs sporadically, and only 25% of the patients have a
family history of the disease, suggesting a contribution for
shared genes and environment. However, only 5%-6% of
CRCisduetoinheritedmutationsinmajorCRCgeneswhilst
the remaining of the familial forms likely result from gene-
environment interactions [3] .R a t e so ft h i sc a n c e ri n c r e a s e
with industrialization and urbanisation, further indicating
that environmental factors can likely represent risk factors.
Diet is deﬁnitely the most important exogenous factor
identiﬁed so far in the etiology of colorectal cancer.
CRC progresses through a series of clinical and histo-
pathologicalstagesranging from single cryptlesionsthrough
small benign tumors (adenomatous polyps) to malignant
cancers (carcinomas). Stages are usually deﬁned by the
tumor-node-metastasis (TNM) classiﬁcation, as deﬁned by
the American Joint Committee on Cancer (AJCC). TNM is
the most commonly used staging system and is based on
depth of invasion of the bowel wall, extent of regional lymph
node involvement, and presence of distant sites of disease.
ThedepthoftumorinvasiondeﬁnestheTstageandincreases
from T1(invasion ofthesubmucosa)toT4(invasionintothe
serosa or adjacent structures) [4]. Another grading system
is Dukes classiﬁcation that considers the arrangement of the
cells rather than the percentage of the diﬀerentiated cells.
The initial Dukes approach has evolved into the three-grade
system. Grade 1 is the most diﬀerentiated, with well-formed
tubules and the least nuclear polymorphism and mitoses.
G r a d e3i st h el e a s td i ﬀerentiated, with only occasional
glandular structures, pleomorphic cells and a high incidence
of mitoses. Grade 2 is intermediate between Grades 1 and 3
[2].
The development of colorectal cancer is a multistep
process that involvesan accumulationofmutationsin tumor
suppressor genes and oncogenes. It has provided a useful
model for the understanding of the multistep process of car-
cinogenesis. The model of colorectal tumorigenesis includes
several genetic changes that are required for cancer initiation
and progression [5]. The earliest trigger genetic event is2 Journal of Biomedicine and Biotechnology
the inactivation of the APC (adenomatous polyposis coli)
pathway. Mutations in other tumor suppressor genes (APC,
SMAD2, 4, TP53) and oncogenes (KRAS) and likely several
other genes/pathways accompany transitions in pathology
of the lesions and drive tumor towards malignancy and
metastasis [6]. Alongside with gene mutations a deregulated
expression of oncogenes and/or tumor suppressor genes
can also occur following epigenetic modiﬁcations of their
promoters.
2.Geneticsof ColorectalCancer
Colorectal cancerrepresents the third most diagnosed cancer
in both men and women. About 75% of the patients have
sporadic forms of the disease. The remaining 25% of the
patients have a family history of the disease, suggesting a
contribution for shared genes and environment. However,
only 5%-6% of CRC is due to highly penetrant inherited
mutations in major genes, whilst the remaining of the
familial forms likely result from interactions between less
penetrant genes and environmental factors [3].
Several studies suggest that ﬁrst degree relatives of an
aﬀected individual diagnosed after age 50 years have a
twofold to threefold increased risk of colorectal cancer.
Moreover, the number of aﬀected family members and age
at cancer diagnosis correlate with disease risk, suggesting
that either having more than one ﬁrst relative with colorectal
cancer or a ﬁrst relative individual diagnosed at an age below
45 years are conditions associated with a threefold to sixfold
increased relative risk. When the family history includes two
or more relatives with colorectal cancer, the possibility of a
genetic syndrome is increased substantially [3, 7].
Other CRC risk factors include the presence of large ser-
rated polyps (serrated adenomas and hyperplastic polyps),
a diet rich in total fat and meat, cigarette smoking, male
gender, the use of nonsteroidal anti-inﬂammatory drugs,
alcohol intake, a sedentary lifestyle, body mass index (BMI)
and abdominal obesity [8–12]. High intakes of folate,
vitamins and dietary ﬁber, colonoscopy with removal of
adenomatous polyps, and postmenopausal hormone use
have been associated with decreased CRC risk [13–16].
2.1. Major CRC Genes and Syndromes. Some inherited
conditions predispose an individual to the development of
colorectal cancer. The study of these CRC syndromes has led
to the identiﬁcation of several major CRC genes (Table 1).
Among major CRC genetic syndromes there are familial
adenomatous polyposis (FAP), attenuated FAP (AFAP),
MUTYH-associated polyposis (MAP), and Lynch syndrome
(hereditary nonpolyposis colorectal cancer HNPCC). Rare
syndromes include hamartomatous polyposis conditions
(Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome
(JPS), and others) and hyperplastic polyposis (Table 1).
2.1.1. Familial Adenomatous Polyposis (FAP), Attenuated
FAP (AFAP), and Gardner Syndrome. FAP is an autosomal
dominant condition characterized by the development of
multiple (hundreds to thousands) adenomas in the rectum
and colon after the ﬁrst decade of life, that inevitably
result in CRC development in untreated subjects. Males and
females are equally likely to be aﬀected. FAP accounts for
less than 1% of CRC cases, with an estimated prevalence
of 1/11,300–37,600 in the European Union [17]. FAP may
present with some extraintestinal manifestations such as
osteomas, dental abnormalities, congenital hypertrophy of
the retinal pigment epithelium, and extracolonic tumours
(desmoid tumors, stomach tumors, duodenum/small bowel
tumors, thyroid cancers, pancreas tumors, hepatoblastoma,
and central nervous system tumors) [3, 17]. Attenuated FAP
(AFAP) is a less aggressive variant of FAP, characterized by
fewer colorectal adenomatous polyps (usually 10 to 100), an
average 69% lifetime risk of CRC, and later age of adenoma
appearance. Some extracolonic tumors also occur in AFAP,
including duodenum/periampullary and thyroid cancers [3,
17]. Gardner syndrome is a variant of FAP and results
in the manifestation of numerous external and internal
symptoms including gastrointestinal polyps, osteomas, den-
tal anomalies, desmoid tumors, and epidermoid cysts [18].
FAP, attenuated FAP, and Gardner syndrome all result from
germline mutations in the tumor suppressor Adenomatous
Polyposis Coli (APC) gene on chromosome 5q21, which
encodes a protein acting as an essential negative regulator
in the evolutionarily conserved Wnt/Wingless (Wg) signal
transduction pathway [19]. Disease severity and the presence
of extracolonic manifestations seem to be correlated with
the location of the mutation within APC. Severe polyposis
(>1000 adenomas) is found in patients with mutations
between codons 1250 and 1464. AFAP is correlated with
mutations before codon 157, after codon 1595, and in the
alternatively spliced region of exon 9. Mutations in the
remainder of the APC gene cause an intermediate phenotype
(hundreds to thousands of adenomas). Congenital hypertro-
phies of the retinal pigment epithelium and desmoid tumors
are associated with mutations between codons 311 and 1444
and after codon 1444, respectively [20].
2.1.2. MUTYH-Associated Polyposis (MAP). MUTYH-asso-
ciated polyposis (MAP) is an autosomal recessive disorder
characterised by adenomatous polyps of the colorectum and
a very high risk of colorectal cancer. It shares important
gastroenterological features with autosomal dominant FAP.
The colonic phenotype of MAP mimics AFAP, and the
burden of adenomas ranges from very few to hundreds.
Key extracolonic manifestations include a predisposition to
duodenal adenomas and cancer and a modest increase in
risk for several extraintestinal tumors [3, 21]. The disease
is caused by biallelic MUTYH mutations [22]. The Mut
Y homolog (MUTYH) gene, located on chromosome 1p,
encodes a protein of the DNA base excision repair pathway
whose impaired function leads to increased G:C to T:A
transversions. The two common MUTYH variants observed
in MAP patients are Tyr165Cys and Gly382Asp [22].
2.1.3. Lynch Syndrome (Hereditary Nonpolyposis Colorectal
Cancer or HNPCC). Lynch syndrome (LS), also known as
hereditary non-polyposis colorectal cancer or HNPCC, isJournal of Biomedicine and Biotechnology 3
Table 1: Major CRC genes and syndromes.
Gene(s) Syndrome Inheritance Lifetime CRC risk
APC FAP Autosomal dominant 100%
APC AFAP Autosomal dominant 69%
MUTYH MAP Autosomalrecessive 80%
MLH1, MSH2, MSH6, PMS2, TACSTD1 (EpCAM) LS Autosomal dominant 80%
STK11 PJS Autosomal dominant 39%
SMAD4 (DPC4), BMPR1A JPS Autosomal dominant 39%
PTEN CS Autosomal dominant rare
an autosomal dominant condition caused by mutations in
one of several DNA mismatch repair (MMR) genes and
represents the most common hereditary CRC predisposing
syndrome, accounting for approximately 3% of the total
CRCs. Unlike FAP, polyposis is rare. Carriers of a Lynch
syndrome gene mutation have an estimated 80% lifetime
risk of developing CRC [23]. Colon cancers are most
likely to develop in the right side, they frequently show
mucinous or signet ring cell morphology, are characterized
by lymphoid aggregates at the periphery of the tumorand/or
lymphocytes inﬁltrating the tumor, and have an elevated
frequency of microsatellite instability [23]. In addition to
CRC, patients with Lynch syndrome and their relatives are
at increased risk for several types of cancers, including
endometrial adenocarcinoma and gastric, ovarian, biliary,
urinary tract, small bowel, brain, and pancreatic cancers
[3]. Muir-Torre syndrome (MTS) is considered a variant of
Lynch syndrome; it is a rare disorder characterized by the
presenceofatleastonesebaceousglandneoplasmandatleast
one visceral malignancy. Sebaceous adenomas, sebaceous
carcinomas, and sebaceous epitheliomas are all characteristic
glandular tumors of MTS. The most common visceral
malignanciesassociated with MTSare colorectal,followedby
genitourinary. These visceral malignancies frequently have a
more indolent course in patients with MTS than they would
otherwise. Muir-Torre syndrome is an autosomal dominant
disorder, often associated with germline mutations in the
MSH2,a n dt h eMLH1 genes [24]. The genes responsible
for Lynch syndrome include MSH2 (mutS homolog 2)o n
chromosome 2p16, MLH1 (mutL homolog 1)o nc h r o -
mosome 3p21, MSH6 (mutS homolog 6) on chromosome
2p16, and PMS2 (postmeiotic segregation 2) on chromosome
7p22. These genes encode for MMR proteins that correct
base mismatches or small insertions or deletions occurring
duringDNAreplication.TheirmutationsinLynchsyndrome
individualsaccountforthemicrosatelliteinstabilityobserved
in tumor cells. MSH2 and MLH1 mutations account for
most of the cases of Lynch syndrome, and several recurrent
or founder mutations have been identiﬁed in these two
genes. For example the founder mutation in Ashkenazi Jews
(MSH2 1906G>C), a genomic deletion of exon 16 of MLH1
that probably dates back 1000 years or more and accounts
for >50% of all Lynch syndrome in Finland, a genomic
deletion of exons 1–6 of MSH2 in German American
populations, and the recurrent A → Tt r a n s v e r s i o ni nt h e
donor splice site of intron 5 of MSH2 (designation c.942 +
3A → T), that occurs worldwide and may account for
as much as 5%–10% of all Lynch syndrome (for a review
see [23]). MTS is often associated with germline MSH2 or
MLH1 mutations, though sporadic cases are known [24].
In addition to MSH2, MLH1, MSH6, and PMS2 mutations,
little evidence suggests that some cases of Lynch syndrome
might be due to germline MLH3 variants [25, 26]. Recently,
germline deletions in the TACSTD1 gene (also known as
epithelial cell adhesion molecule gene: EpCAM) have been
identiﬁed in families with Lynch syndrome resulting in
multiple TACSTD1/MSH2 fusion transcripts and epigenetic
inactivation of the corresponding MSH2 allele [27, 28].
2.1.4. Hamartomatous Polyposis Conditions: Peutz-Jeghers
Syndrome, Juvenile Polyposis Syndrome, Mixed Polyposis Syn-
drome, and Others. Peutz-Jeghers syndrome (PJS) is an
inherited, autosomal dominant disorder distinguished by
hamartomatous polyps in the gastrointestinal tract and
pigmented mucocutaneous lesions, typically presenting in
childhood on the lips, buccal mucosa, and perioral region.
Prevalence of PJS is estimated from 1 in 8300 to 1 in 280,000
individuals.PJSpredisposessuﬀererstovariousmalignancies
(gastrointestinal, pancreatic, lung, breast, uterine, ovarian
and testicular tumors) [29, 30]. The majority of patients that
meettheclinicaldiagnosticcriteriahaveacausativemutation
in the tumor suppressor STK11 gene, located at 19p13.3,
encoding a serine threonine kinase (STK) protein [31].
Juvenile polyposis syndrome (JPS) is a rare, early-onset
disease, characterized by the presence of hamartomatous
polyps throughout the gastrointestinal tract [32]. The
lifetime CRC risk in JPS individuals is estimated to be
39% [33]. It is estimated that 15%–20% of JPS patients
carry autosomal dominant mutations in the SMAD4/DPC4
(deleted in pancreatic cancer locus 4) gene, on chromosome
18q21.1, that encodes a critical cytoplasmic mediator in
the transforming growth factor-beta signaling pathway [34],
whereas 25%–40%ofthepatientscarry autosomal dominant
mutationsin thegeneencodingbonemorphogenetic protein
receptor 1A (BMPR1A),onchromosome 10q22-23[35].The
rest of JPS cases appear to be sporadic.
Hereditary mixed polyposis syndrome (HMPS) is char-
acterized by polyps of mixed adenomatous/hyperplastic/
atypical juvenile histology that are autosomal dominantly
inherited and that eventually lead to colorectal cancer. There
is consistent phenotypic overlap between JPS and HMPS.
A recent study showed that germline BMPR1A defect is the4 Journal of Biomedicine and Biotechnology
CRC causing mutation in 50% of Singapore Chinese HMPS
families [36]. Linkage between HMPS and chromosome 15q
has also been reported [37].
Cowden syndrome (CS) is another rare autosomal
dominanthamartomatouspolyposiscondition.27%–43%of
CS patients have been shown to have hamartomatous polyps
in the gastrointestinal tract; however, CS seems to confer
little, if any, CRC risk [32]. The disease is caused in most of
the cases by mutations of the tumor suppressor phosphatase
and tensin homolog (PTEN)g e n e[ 38].
2.1.5. Hyperplastic Polyposis Syndrome (HPPS). HPPS is a
rare condition characterized by the presence of multiple
and/or large hyperplastic polyps throughout the colon
that predisposes 50% or more of the patients to CRC
development [39]. The World Health Organization (WHO)
established that the diagnosis of HPPS must accomplish one
of the following criteria: (1) at least ﬁve hyperplastic polyps
occurring proximal to the sigmoid colon (of which at least
twoshouldbelargerthan10mm indiameter);(2)Morethan
30 hyperplastic polyps distributed throughout the colon; (3)
atleast onehyperplastic polypproximalto thesigmoid colon
inan individualwho hasatleastoneﬁrst-degree relativewith
HPPS [40]. Little is still known about the etiology and the
genetics of this condition.
2.1.6. Familial Colorectal Cancer (FCC). As detailed in the
introduction of this section, a family history of colorectal
cancer (i.e., one or more relatives with CRC) confers a
twofold to sixfold increased CRC risk, depending on the
number of aﬀected family members and the age at diagnosis
of the aﬀected relatives. Even if it is estimated that familial
clusters of CRC account for almost 20% of CRCs in devel-
oped countries, the rare CRC syndromes described above
contributeonlytoafractionofthem,suggestingtheexistence
of other less penetrant genes and/or gene-environment
interactions at the basis of familial CRC aggregates The term
familial colorectal cancer (FCC) is used to categorize CRC
families that do not meet the clinical criteria for a diagnosis
of known hereditary CRC syndromes. Several approaches
have been performed to identify less penetrant loci that
might contribute to familial CRC, including family linkage,
aﬀected relative pair studies, and genome-wide association
studies. Some of these studies have identiﬁed potential loci
onchromosomes 8,9,11,and 18(seethereviewbyJasperson
et al. [3], and the next section).
2.2. Genetic Polymorphisms and Colorectal Cancer Risk.
Polymorphisms underlying genetic susceptibility to CRC
have been investigated either by means of the classical
candidate gene approach (based on the known function of
the gene and its relevance in pathways likely involved in
CRC pathogenesis) or, more recently, by means of genome-
wide association studies (GWAS) where half a million or
more single nucleotide polymorphisms (SNPs) are tested
simultaneously in a large case-control cohort. A contin-
uously updated overview of the genetic polymorphisms
associated with CRC risk can be found at the NCI website
(http://www.cancer.gov/cancertopics/genetics/colorectal/
healthprofessional). Table 2 lists some examples of genesand
loci associated with CRC risk.
2.2.1. Candidate Gene Approaches and Meta-Analyses. Spo-
radic CRC is considered to be a multifactorial disease, in
which multiple exposures to endogenous factors interact
with individual genetic background in a complex manner,
resulting in modulation of the risk. Several genes have
been investigated as candidate CRC risk factors, often with
conﬂicting or inconclusive results, and meta-analyses or
updated reviews of the literature are currently available.
Glutathione S-transferases (GSTs) are particularly attractive
candidatesfor CRCsusceptibility becausethey codeenzymes
involved in the metabolism of environmental carcinogens;
recent meta-analyses of the literature suggest that both
GSTM1 and GSTT1 null genotypes are associated with
an increased risk of CRC, especially in the Caucasian
populations [41–43]. Conﬂicting results have been obtained
concerning DNA repair gene polymorphisms and CRC
risk [44–46]. Cyclooxygenase-2 (COX2), a key enzyme in
arachidonic acid metabolism, is overexpressed in several
epithelial malignancies including colorectal cancer, and
recent meta-analyses revealed that promoter polymorphisms
of the COX2 gene may be potential risk factors for cancers of
the digestive tract in Asians, including colorectal cancer [47–
49]. Polymorphisms of genes involved in folate metabolism,
such as methionine synthase (MTR) and methylenetetrahy-
drofolate reductase (MTHFR), might also increase CRC
risk [50, 51]. Interaction between smoking status and N-
acetyltransferases (NAT1 and NAT2) polymorphisms seem
to aﬀect CRC risk [52]. TGF-beta1, its receptor TGFbetaRII,
and the signaling proteins Smad4 and Smad7 have been
observed in the majority of colorectal cancer tissues [53].
Conﬂicting results have been obtained concerning TGFbeta
receptor I (TGFBR1) polymorphisms and CRC risk [54],
whilst increased risk of colon cancer was associated with
variants of SMAD7 in several studies [55–58]. The I1307K
polymorphism in the APC gene occurs almost exclusively in
Ashkenazi Jews and increases the risk of colorectal cancer
[59]. Some polymorphisms also aﬀect the phenotype of
Lynch syndrome (HNPCC). For example, age at onset of
CRC in HNPCC is modiﬁed by a promoter polymorphism
of the insulin-like growth factor gene (IGF1)[ 60, 61].
2.2.2. Genome-Wide Association Studies (GWAS). Large
genome-wide association studies (GWAS) identiﬁed several
loci as possible common low-risk susceptibility alleles,
including8q23.3,8q24, 10p14,11q23,15q13,and 18q21 [62,
63]. A meta-analysis of those GWAS revealed four additional
susceptibilitylocion14q22.2,16q22.1,19q13.1,and20p12.3,
in addition to the six loci previously identiﬁed [64]. A
recent GWAS in German familial CRC cases conﬁrmed
the two previously reported loci at 8q24 and 11q23, and
suggested novel polymorphisms (rs12701937, rs6038071,
and rs11014993) associated with CRC in familial cases [65].
2.3. Genes Involved in CRC Progression: TP53 and K-RAS.
MutationsinTP53andK-RASdonotcauseCRCsyndromes,Journal of Biomedicine and Biotechnology 5
Table 2: Some of the genes or loci associated with CRC risk (see the text for details).
Gene or locus Type of study Comment
GSTT1 Meta-analysis of genetic association studies GSTT1 null genotype associated with increased CRC
risk (Caucasians)
GSTM1 Meta-analysis of genetic association studies GSTM1 null genotype associated with increased CRC
risk (Caucasians)
COX2 Meta-analysis of genetic association studies Promoter polymorphisms associated with increased
CRC risk (Asians)
MTHFR Meta-analysis of genetic association studies MTHFR 677C>T associated with increased CRC risk
NATs Gene-environment interaction Interaction between NATs polymorphismsand smoking
status aﬀect CRC risk
MTR Meta-analysis of genetic association studies MTR 2756A>G associated with increased CRC risk
SMAD7 Genetic association studies and GWAS SMAD7 variants associated with increased CRC risk
APC Genetic association studies APC I1307K associated with increased CRC risk in
Ashkenazi Jews
IGF1 Genetic association studies IGF1 promoter polymorphisms associated with
HNPCC age at onset
8q23.3 GWAS Associated with CRC risk
8q24 GWAS Associated with CRC risk
10p14 GWAS Associated with CRC risk
11q23 GWAS Associated with CRC risk
15q13 GWAS Associated with CRC risk
14q22.2 Meta-analysis of GWAS Associated with CRC risk
16q22.1 Meta-analysis of GWAS Associated with CRC risk
18q21 GWAS Associated with CRC risk
19q13.1 Meta-analysis of GWAS Associated with CRC risk
20p12.3 Meta-analysis of GWAS Associated with CRC risk
however; they are the genetic abnormalities most exhaus-
tively implicated and studied in CRC progression. TP53
encodesa transcription factor (p53) deﬁned as the “guardian
of the genome” since it is involved in the coordination of
cellular responses to oxidative stress, DNA damage, cell cycle
regulation, apoptosis, and many other pathways. Loss of
TP53 function through gene mutation is a critical event in
the development and progression of many tumour types
including CRC. The majority of TP53 mutations occur in
t h ec o r ed o m a i nw h i c hc o n t a i n st h es e q u e n c e - s p e c i ﬁ cD N A
binding activity of the protein, and they results in loss
of DNA binding. Inactive TP53 mutations were found in
29% of all CRCs and were more frequent in rectal than
proximal colon tumours. TP53 mutations were associated
with lymphatic invasion in proximal tumors, and with worse
survivalindistaltumors.HigherfrequenciesofinactiveTP53
mutations were also seen in advanced-stage tumours and
in tumours with the poor prognostic features of vascular
and lymphatic invasion. Inactive TP53 mutations have been
associated with signiﬁcantly worse outcome only in patients
with Dukes stage D tumours [66, 67].
The RAS signalling pathway is involved in growth
diﬀerentiation, cell survival, cell proliferation, apoptosis,
cytoskeleton organization and function, inﬂammation, and
cell transformation. A glycine to valine mutation on codon
12 of K-RAS, found in 8.6% of all patients, had a statisti-
cally signiﬁcant impact on failure-free survival and overall
survival. This mutation also appeared to have a greater
impact on outcome in Dukes’ C cancers than in Dukes’
B tumours. The study demonstrated that not only is the
presence of a codon 12 glycine to valine mutation important
for cancer progression, but also that it may predispose
to more aggressive biological b e h a v i o u ri np a t i e n t sw i t h
advanced colorectal cancer [68].
3.CytogeneticsofColorectalCancer:
The CINPhenotype
For colorectal cancers, the acquisition of genomic instability
is considered a key hallmark. Three major molecular sub-
types can be recognized: MIN (or MSI, for “microsatellite
instability”),CIN(for“chromosomal instability”)andCIMP
(for“CpGislandmethylatorphenotype”)[79,80].MINCRC
accounts for approximately 15%–20% of sporadic colorectal
cancers. It is a well-deﬁned subtype that results from a loss
of DNA mismatch repair function, secondary to inactivation
of MMR genes (see Lynch syndrome, Section 2.1.3). MIN
tumors were at the beginning believed to be near-diploid
with few, if any, karyotypic abnormalities [77]. However
in MSI tumors, the pathway of chromosome gains is
frequently observed whereas that of chromosomal losses is
rarely found [75]. On the other hand the deﬁnitions of the
three pathways (MIN, CIN, and CIMP) are not completely6 Journal of Biomedicine and Biotechnology
Table 3: The most frequent aberrations found in CRC (see the text for details).
Chromosomeloss Chromosomegain References
18, 17p, 1p, 4, 14, 5q, 21 7, 12, X, 5, 8 Dutrillaux, 1988 [69]
18q21 Fearon et al., 1990 [70]
20q13 Korn et al., 1999 [71]
18q 20q De Angelis et al., 1999 [72]
18p21-pter, 15q11-q21,
17p12-13, 18q12-21 8q23-ter, 13p14-31, 20q13 Hermsen et al., 2002 [73]
4, 18p, 14q 17p, 17q, 1q11, 12p, 19 Diep et al., 2006 [74]
8p, 18q, 1p22, 4q26, 15q21 20, 8q, 8q28, 16q24.3, 20q13 Camps et al., 2006 [75]
18q 13q Fensterer et al., 2007 [76]
18, 17p, Y, 1p3, 8p 13, 20, 7, X, 12, 6 Muleris et al., 2008 [77]
8p, 18, 18q 3, 3q, 5, 5p, 5q, 7, 8q, 20, 20q, 13, X Knutsen et al., 2010 [78]
4, 5, 8, 10, 14, 15, 17, 18,
21, 22, Y, 18q10 [i(8)
(q10)], 17q10 [i (17) (q10)]
7, 13, 20, X Mitelman Database online
deﬁned and thus not mutually exclusive, it is believed that a
tumor can occasionally show features of multiple pathways,
although the extent and nature of this overlap remains to be
determined [77, 81].
CIN is the most common type of genomic instability
observed in colon cancer and occurs in 80%–85% of
colorectal tumors [82]. It occursmainly in non-MIN cancers
(or MSS for “microsatellite stable”) which are proﬁcient for
mismatch repair.
CIN CRC show several forms of genomic instability,
characterized mainly by chromosomal rearrangements and
numerical abnormalitiesata greatlyincreased ratecompared
with normal cells [83].
Originally, the CIN phenotype was used to describe
tumors with a high degree of intercellular heterogeneity in
chromosome number, ascertained by counts for a restricted
set of chromosome-speciﬁc centromeres [79]. CIN was
further employed to describe cancers with either aneuploid
or polyploid DNA content as measured by cytometry or
cytogenetics, or multiple gains or deletions of chromosomes
or chromosome arms, or frequent losses of heterozygosity
(LOH) [79]. The ﬁrst cytogenetic observations on cancer
cells from colorectal adenocarcinomas were described by
Dutrillaux [69]. With classical cytogenetic approach he
observed two distinct patterns of chromosomal anomalies.
The ﬁrst one, called “monosomic type”, was characterized by
many chromosomes losses, including the losses or deletions
of chromosomes 18, 17 (short arm = p), 1p, 4, 14, 5 (long
arm = q) and 21. He noticed that this condition frequently
evolves towards polyploidy, by duplication of all remaining
chromosomes. The second pattern, called “trisomic type”,
was characterised by the gain of several chromosomes: 7, 12,
X, 5 and 8. The chromosomal anomalies observed seemed at
thattimetohavenotopologicalrelationshipswithoncogenes
[69]. Indeed subsequently it became clearer that the cancer-
speciﬁc aneuploidies generate complex, malignant pheno-
types, through the abnormal dosages of the thousands of
genes [84].
In general, genomic copy number changes are frequently
found in diﬀerent types of cancer and are believed to
contribute to their development and progression through
inactivation of tumour suppressor genes, activation of
oncogenes, or more subtlly through gene dosage changes
[76]. Chromosomal instability is an eﬃcient mechanism for
causing the physical loss of a wild-type copy of a tumor-
suppressor gene, such as in CRC: APC, TP53,a n dS M A D
family member 4 (SMAD4), whose normal activities oppose
the malignant phenotype [85]. The ﬁrst cytogenetic studies
on primary CRC tumors suﬀered by limitations due to
the poor quality of the preparations. The improvement of
molecular cytogenetic studies, performed subsequently with
the application of ﬂuorescence in situ hybridization (FISH)
basedtechniquessuch ascomparativegenomichybridization
(CGH) and spectral karyotyping (SKY), allowed many
groups to show that colorectal carcinomas are characterized
by multiple patterns of chromosomal imbalances which
sequentially accumulate during adenoma to carcinoma pro-
gression [73].
Among the ﬁrst ﬁndings, Fearon et al. [70]c o n ﬁ r m e d
a frequent genomic loss in CRC at chromosome 18q21. By
using comparative genomic hybridization (CGH) Korn et al.
[71]foundthatmostfrequentgainsareat20q13andwiththe
s a m et e c h n i q u eD eA n g e l i se ta l .[ 72] determined that gains
of 20q and losses of 18q were the most frequent aberrations.
Accumulation of losses in 8p21-pter, 15q11-q21, 17p12-
13, and 18q12-21, and gains in 8q23-qter, 13q14-31, and
20q13 were found strongly associated with adenoma-to-
carcinoma progression, independent of the degree of dyspla-
sia [73].
Diep et al. [74] by applying diﬀerent statistical analyses
and combining these on a large series of genome proﬁles
from reported CRC, were able to identify speciﬁc chromo-
somal alterations linked to the diﬀerent stages of tumor
progression. They found that losses at 17p and 18 and
gains of 8q, 13q, and 20 occur early in the establishment
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transition from Dukes’ A to B–D stages. They observed
that deletion of genes located at chromosome 4 might
thereforecontributetoincreasedaggressivenessofthetumor,
enabling it to penetrate the muscular layer, and contribute
to the establishment of advanced stages; moreover loss of
chromosome 4 has been shown to be associated with poor
clinical outcome in a large series of CRC [74]. The transition
from primary tumor to liver metastasis results correlated
with the deletion of 8p and gains of 7p and 17q, whereas
losses of 14q and gains of 1q, 11, 12p, and 19 are late events.
In a pilot study by Fensterer and coworkers [76]u s i n g
macrodissected paraﬃn-embedded tissue samples, matrix-
CGHwasperformed.Themajorityofadvancedtumoursdis-
played 13q-gain and 18q-loss. In locally restricted tumours,
only half tumours showed a gain on 13q and 7/12 tumours
showed a loss on 18q. Interphase-FISH and high-resolution
arraymapping of the gain on 13q conﬁrmed the validity
of the arraydata and narrowed the chromosomal interval
containing potential oncogenes. The ampliﬁcation on 13q
appeared to harbour candidate genes that might confer a
more aggressive phenotype to colorectal cancer cells [76].
Finally, to summarize the numerous investigations per-
formed in the last decade in primary colon cancer tumors,
including the recent study by Knutsen and co-workers,
comparing the CGH patterns in all of these reports, gains
were most frequent for 3/3q, 5/5p/5q, 7, 8q, 20/20q, 13,
and the X, and losses were most frequent for 8p and
18/18q [78]. Searching for the most frequent structural and
numerical aberrations found in the large intestine adeno-
carcinoma specimens in the Mitelman Database of Chro-
mosome Aberrations in Cancer (http://cgap.nci.nih.gov/
Chromosomes/Mitelman), among unbalanced Chromoso-
mal Abnormalities there are 8q10 i(8)(q10) and 17q10
i(17)(q10); among numerical trisomies +7, +13, +20, and
+X; among monosomies −4, −5, −8, −10, −14, −15, −17,
−18, −21, −22, and −Y. The most recurrent aberration
found in all cytogeneticstudies performed, either in primary
tumors or in colon cancer cell lines or in ﬁxed colorectal
cancer tissue blocks is thus 18q (Table 3). LOH of this
region indicates an unfavorable outcome in patients with
stage II CRC [86]. In the 18q21-18q21.1 region several
tumor suppressor genes have been mapped, including
SMAD4/DPC4. However, since microsatellite instability was
inversely correlated with loss of heterozygosity for chromo-
somes 5q, 17p, and 18q, it has been hypothesized that some
colorectal cancers (MSI in particular) may arise through a
mechanism that does not necessarily involve loss of hetero-
zygosity [87].
3.1. Mechanisms Responsible of Chromosome Instability in
CRC. In these last years, there has been intense interest
in identifying the mechanisms responsible for the CIN. In
most carcinomas, including CRC, chromosomal instability
proceeds through two major mechanisms, missegregation
that results in aneuploidy through the gain or loss of whole-
chromosomes, and unbalanced structural rearrangements
(unbalanced translocations, deletions, isochromosomes, ...)
that lead to the loss and/or gain of chromosomal regions
[77]. Lengauer and co-workers [79] showed ﬁrst that CRC
tumors without MIN exhibit a striking defect in chro-
mosome segregation, resulting in gain, or losses in excess
of 10−2 per chromosome per generation. They performed
cell fusion experiments between CIN and non-CIN cells
(transfected HT-29 cells) and showed that the CIN pheno-
type acts dominantly at the cellular level, suggesting that it
can arise from gain-of-function mutations; aneuploidy was
considered indeed the result of an abnormally high rate of
CIN [79].
Muleris et al. [77] performed a study to address the
question if CIN occurs mainly as the consequence of either
missegregation ofnormalchromosomes(MSG)orstructural
rearrangement (SR)bykaryotypingaconsecutiveseriesof96
near-diploid colorectal cancers. MSGs and SRs were found
not randomly associated within tumors, delineating two
major pathways of chromosome alterations that consisted of
either chromosome gains by MSG or chromosomal losses by
both MSG and SR [77].
Recently Knutsen et al. [78] reviewed the karyotypes of
345 cases of adenocarcinoma of the large intestine listed
in the Mitelman Database of Chromosome Aberrations in
Cancer and compared them with the types of abnormalities
observed in 15 established colorectal cancer cell lines,
reﬂecting those seen in primary tumors, using spectral
karyotyping (SKY), ﬂuorescence in situ hybridization, and
comparativegenomichybridization (CGH).They found that
there were no recurrent translocations in either tumors or
cell lines; isochromosomes were the most common recurrent
abnormalities; and breakpoints occurred most frequently at
the centromeric/pericentromeric and telomere regions. They
concluded that copy number alterations appear to be the
major mechanism for transcriptional deregulation of cancer
genes in CRC [78].
Other research groups performed studies addressed to
identify proteins that regulate the ﬁdelity of chromosomes
(regulation of DNA ﬁdelity during DNA replication and
in response to genotoxic stress) either by means of model
organisms, such as yeasts, Drosophila and mice. Chromoso-
mal instability is considered the result of somatic mutations
in genes that regulate the mitotic spindle checkpoint,
DNA replication checkpoints, DNA damage checkpoints,
chromosome metabolism,andcentrosomefunction [81,82].
In particular, studies were concentrated on three functional
pathways: defects in proteins that are involved in double-
strand break repair, kinetochore function, and chromatid
segregation [88]. Within this context, Pino and Chung [81]
observed that although over 100 genes can cause chromoso-
mal instability in the yeast Saccharomyces cerevisiae,o n l ya
few of them have been observed in human tumors. Genes
such as hMAD, hBUB1, hBUBR1, hZw10, hZwilch, hRod,
CENP-A, CENP-H, and APC are involved in the mitotic
checkpoint that allows a proper chromosome separation.
Mutations of these genes have been found in human
cancers,forexamplemutatedhMAD1andhMAD2havebeen
found in leukaemia and breast cancer, mutations of hZw10,
hZwilch, and hRod have been found in CRC, and mutations
of hBUB1 and hBUBR1 resulted in no checkpoint arrest in
cancer cell lines [81]. The role of APC in CRC pathogenesis
has been largely described in Section 2.1.1.T h eAPC gene8 Journal of Biomedicine and Biotechnology
product is involved in the Wingless/Wnt signal pathway and
has a role even in chromosome segregation. Other categories
of genes that might contribute to the CIN phenotype in
CRC tissues are those involved in centrosome function
and duplication, such as those encoding the protein kinase
Aurora A (AURKA) and the serine/threonine kinase Plk1
(PLK1), and those involved in the DNA damage response
machinery, particularly TP53 [81]. Diep and co-workers (see
previous paragraph) supplemented their ﬁndings aimed at
the identiﬁcation of chromosomal aberrations that diﬀeren-
tiate among the Dukes’ stages of colorectal cancer as well
as those that are responsible for the progression into liver
metastases, with a listofpotentialtargetgenesforthespeciﬁc
alterations from a publicly available microarray expression
dataset of CRC [74]. For instance a gene that shows reduced
expression in colorectal carcinomas is CENT1, located at
18p11.32. The relative protein, a member of the calcium-
binding EF-hand protein super-family, has an important
role in the determination of centrosome position and
segregation, and in the process of microtubule severing. One
of the early changes is gain of 20q; the expression data
revealed a potential candidate gene for this chromosomal
alteration MYBL2, located at 20q13.12 and directly regulated
by the CDKN2A/CCND/RB/E2F pathway along with many
critical S-phase genes; increased expression of this gene has
beenobserved in several tumors [74]. The expression dataset
revealed moreover that IGFBP1 as a gene that may be one
of the targets for gain of 7p.I G F B P 1 ,a ni n s u l i nl i k eg r o w t h
factor-binding protein, has been observed to have an eﬀect
oncellgrowth,andincreasedexpression ofthisgenehasbeen
seen in diﬀerent cancer types [74].
Barber et al. [89], through bioinformatic approaches
compared 102 human genes highly related to 96 yeast CIN
genesand showed that downregulation or genetic disruption
of genes directly involved in sister chromatid cohesion (such
as MRE11A and CDC4) play a major role in the CIN
phenotype in human colorectal tumors [89].
The comparison of array-CGH and gene expression
microarray data for primary CRCs and CRC cell lines
showed thatMSI-associated geneexpression changes broadly
reﬂect systematic DNA copy-number diﬀerences between
MSI tumors, which tend to be near-diploid, and MSS
tumors, which tend to be aneuploid [90]. These data
demonstrate that DNA copy number changes in cancer cells
have profound eﬀects on gene expression, and therefore, this
mechanism contributes to the clinical diﬀerences between
MSI and MSS tumors.
Either TP53 or K-RAS mutations are involved in CRC
progression and, given their respective functions (see Sec-
tion2.3),bothgenescouldcontributetoCIN[81].According
to Pino and Chung [81] other factors that could drive CIN
in CRC are telomere dysfunction and loss of heterozygosity
(LOH) for the genes on 18q.
3.2.CytogeneticAberrations inCRC as Biomarkers. Ingeneral
cytogenetic aberrations found in cancers are considered
biomarkers for disease since they can provide diagnos-
tic, prognostic, and treatment-related information for the
associated cancers. However in CRC molecular biomarkers
instead of cytogenetic ones are more studied and stan-
dardized, compared to other cancers. For example, germ-
line mutations in tumor-suppressor genes, such as APC,
MLH1,a n dMSH2, indicate a very high risk of colorectal
cancer and guide the frequency of CRC surveillance and
recommendations for prophylactic surgery [85]( s e ea l s ot h e
previous Section 2.1).
A few genomic markers are useful for prognosis.
Microsatellite instability and loss of heterozygosity at chro-
mosome 18q are the two best-deﬁned molecular prognostic
markers [91].
Studies have been performed to understand functional
relevance of chromosomal aberrations for colorectal cancer
progression but these somatic markers have modest or
unconﬁrmed prognostic value and are not currently used
to direct care. Patients with MSI sporadic colorectal cancers
generally have a favorable prognosis [91]; poor survival in
stage II and III colon cancers is associated with the loss of
p27 (a proapoptotic regulator of the cell cycle) or the loss of
heterozygosity at chromosomal location 18q [78,M a k o w i t z
et al., 2009]. However in a large prospective study of patients
with non-MSI-high colorectal cancer, 18q LOH or allelic
imbalance was not associated with patient survival [92].
Mutations in K-RAS, observed in approximately 40%
of colon tumours, have signiﬁcant implications for pre-
dicting likelihood of response to the antibody-based EGFR
inhibitors (cetuximab and panitumumab) therapy, with K-
RAS mutant patients now clearly shown to be inherently
resistant to these agents [1].
4.Epigeneticsand ColorectalCancer
Epigeneticsis deﬁned asheritable changes ingene expression
that are not accompanied by changes in DNA sequence.
An epigenetic modiﬁcation is DNA methylation, a covalent
additionofa methyl group (CH3)tothe nucleotidecytosine.
In mammals, most of the DNA CpG sites are methylated
(90%–98%), but there are speciﬁc CpG-rich areas of DNA
where most CpGs are not methylated (CpG islands); a
few genes are imprinted genes, regulated by methylation
of the CpG islands in their promoter, and the markings
are stably replicated during cell division but are reversed
when inherited through an individual of the opposite sex.
Promoter hypomethylation has been associated with an
increased gene transcription. DNA hypermethylation occurs
at speciﬁc regulatory sites in the promoter regions or
repetitive sequences. Aheavy density ofcytosine methylation
in the CpG islands of the tumor suppressor gene promoters
canleadtoacompleteblockoftranscription, andmany types
of cancer use this mechanism to inactivate tumor suppressor
genes.Epigeneticeventsare a characteristic of human cancer,
including CRC. Other epigenetic modiﬁcations include
histone acetylation and gene silencing mediated by small
noncoding RNA (microRNA or miRNA). Table 4 shows
epigenetic alterations observed in CRC.
4.1. DNA Methylation in CRC. Methylation of CDKN2A,a
tumour suppressor gene, is detected in 40% of colorectalJournal of Biomedicine and Biotechnology 9
Table 4: Epigenetic alterations in colorectal cancer.
Genes involved in CRC Gene functions and epigenetic changes
APC Adenomatosis polyposis coli Tumour suppressor gene, antagonistof Wnt signalingpathway.
MGMT O-6-methylguanine-DNA
methyltransferase
Involved in repairing DNA damage; silencing by hypermethylation correlates with
G to A mutations in the K-RAS oncogene.
CDKN2A/P14 Cyclin-dependent kinase inhibitor 2A,
alternated reading frame
Tumour suppressor gene, involved in cell cycle regulation; its silencing by
hypermethylation is associated with increased risk of CRC.
HLTF Helicase-like transcription factor
This gene encodes for a chromatin remodelling factor. Members of this family have
helicase and ATPase activities and are thought to regulate transcription of certain
genes by altering the chromatin structure around those genes. Its silencing could
increase CRC risk.
hMLH1,
hMLH2 MutL homolog1, 2 DNA repair genes; their silencing,by hypermethylation is associatedwith MSICRC.
CDKN2A/P16 Cyclin-dependent kinase inhibitor 2A
Tumor suppressor gene that plays an important role in regulating the cell cycle;
mutations or inactivation by hypermethylation in the CDKN2A gene are associated
with increased risk of a wide range of cancers.
CDH13 H-cadherin It is a regulator of cellular adhesion-deadhesion processes, and its inactivation
through hypermethylation contributes to the dissemination of cancer cells.
UNC5C Unc-5 homologC UNC5C is one of the Netrin-1 receptors, has tumor-suppressor activity. The loss of
UNC5C expression is particularly prominent in colorectal cancer.
DCC Deleted in colorectal carcinoma
Encodes for a membrane-bound protein of the immunoglobulin-CAM family and
may function as tumor suppressor gene which controls programmed cell death.
DCC has been identiﬁed on a region of chromosome 18, which is deleted in 70% of
colorectal cancer.
COX2 Prostaglandineendoperoxide
synthase 2 Involved in inﬂammationand mitogenesis, tumour angiogenesis and metastasis.
HACE 1 E3 ubiquitin ligase H A C E 1m i g h ta c ta sat u m o rs u p p r e s s o ri nc o l o r e c t a lc a r c i n o m a sa n dHACE1
methylation might present a malignantpotential in colorectal cancer.
RASSF1A Ras association(RalGDS/AF-6)
domain family 1
Suppressor protein involved in death receptor-dependent apoptosis and it is
localized to microtubules.
RUNX3 Runt-related transcription factor 3
This gene encodes a member of the runt domain-containingfamily of transcription
factors and can either activate or suppress transcription. It also interacts with other
transcription factors. It functions as a tumor suppressor, and its silencing by
hypermethylation could inﬂuence CRC risk.
SOCS1 Suppressor of cytokine signaling1 SOCS1 is involved in negative regulation of cytokines that signal through the
JAK/STAT3 pathway; its silencing by hypermethylation could inﬂuence CRC risk.
CHFR Checkpoint with FHA and RING
ﬁnger
CHFR functions as part of an early G2/M checkpoint. CHFR might act as a tumor
suppressor and CHFR methylation might, therefore, be a particular phenomenon
of early colorectal cancer.
ADAM23 A disintegrin and metalloproteinase
domain 23
Members of this family are membrane-anchored proteins and have been implicated
in a variety of biological processes involving cell-cell and cell-matrix interactions.
ADAM23 may be downregulated by aberrant promoter hypermethylation during
the progression of colorectal cancer.
DLEC1 Deleted in lung and oesophageal
cancer 1
May act as a tumor suppressor by inhibiting cell proliferation and its silencing by
hypermethylation correlates with CRC risk.
SERF1 Secreted frizzled -related protein 1 Epigenetic silencing of SFRP genes lead to aberrant activation of the Wnt pathway.
MYOD Myogenic factor 3 MyoD removes cells from the cell cycle (halt proliferation) by enhancing the
transcription of p21. Its silencing could inﬂuence CRC risk.
P15 Cyclin-dependent kinase inhibitor 2B
TIS gene is a tumor suppressor, which encodes a cyclin-dependent kinase inhibitor
and it is positively regulated by transforming growth factor- (TGF-).
hypermethylation of the P15 gene promoter, which should silence gene expression,
correlates with CRC risk.10 Journal of Biomedicine and Biotechnology
Table 4: Continued.
Genes involved in CRC Gene functions and epigenetic changes
P73 Tumor protein p73
P73 maps to chromosome region 1p36.3, which is frequently deleted in a variety of
solid tumors. Participates in the apoptotic response to DNA damage. May be a
tumor suppressor protein, so its silencing by aberrant methylation correlates with
CRC risk.
WT1 Wilms tumor 1 I th a sat u m o rs u p p r e s s o ra sw e l la sa no n c o g e n i cr o l ei nt u m o rf o r m a t i o n .T h e n
aberrant methylation could inﬂuence CRC risk.
Cyclin A1 Cyclin A1 Binds to trascription factor E2F-1, p21, Rb family protein; aberrant methylation in
this gene could inﬂuence CRC risk.
MINT Probably represses transcription via the recruitment of large complexes containing
histone deacetylase proteins. May bind both to DNA and RNA.
RAR-b Retinoic acid receptor beta Tumor suppressor gene, mediates the growth inhibitory action of retinoic acid; its
silencing by hypermethylation promotes tumour progression.
CDH5 Chromodomainhelicase
DNA-binding protein 5
Tumor suppressor gene involved in regulating chromatin architecture and in
modifying chromatin structure in an ATP-dependent manner.
RGC-32 Response gene to complement
RGC-32 regulate a group of genes involved in chromatin assembly. RGC-32
knockdown induced an increase in acetylation of histones H2B lysine 5 (H2BK5),
H2BK15, H3K9, H3K18, and H4K8, a decreased expression of SIRT1 and
trimethylation of histone H3K27. RGC-32 silencing is associated with chromatin
remodeling and activation of cell cycle.
miRNA124a It could be repressed by CpG island hypermethylation, relative to normal tissue; it





Methylation of these genes was observed in CRC cell lines and in primary CRC
tumour respect to normal mucosa.
miR-21 Alterated methylation could upregulate this microRNA in colorectal cancer,
promoting invasion and metastasis.
miR-143
Down regulated in colon cancer; expression of K-RAS was found inversely
correlated with this microRNA in vivo; miR-143 was inversely correlated with
mRNA and the protein expression of DNMT3A in CRC.
miR135 Inversed association between this microRNA and the level of APC mRNA was
observed in colorectal adenomas and carcinoma.
miR-34a
miR-34a may act as a tumor suppressor by blocking SIRT1, thereby permitting
increased p53 activity. By deacetylating p53, SIRT1 decreases the ability of p53 to
promote cell cycle arrest. SIRT1 activity may increase the risk of cancer. MiR 34a
silencing, by hypermethylation cannot inhibit SIRT1 activity.
cancers and has been found also in colorectal adenoma.
Methylation of P16 was found in colorectal cancer (Dukes
stage C) suggesting that P16 inactivation was important
for tumorigenesis [93]. Also, Wettergren and co-workers
found an increase of P16 methylation in older than younger
patients; moreover the frequency of P16 hypermethylation
was highest in right-sided colonfollowed by rectum and left-
sided colon. Furthermore patients without methylation of
P16 in mucosa, survived more than patients with hyperme-
thylation [94]. Keyes and coworkers [95] found that aging
causes DNA bypomethylation, but increases p16 promoter
methylation in mouse colons and the eﬀect is dependant on
dietary folate.
Ad i ﬀerent CDH13 methylation between poorly diﬀeren-
tiated colorectal cancer and diﬀerentiated cancer was found.
A signiﬁcant increase of HACE1genemethylation incolorec-
talcancerwasobservedinthemaximal tumoursize. Asignif-
icant alteration of UNC5C methylation in colorectal cancer,
principally in Dukes stage C than in earlier stages was also
observed [93]. Wasson and coworkers [96]d e m o n s t r a t e d
that in folate depleted colon cells, there was an increment
of global DNA hypomethylation; particularly there was a
major hypomethylation in the region of TP53 gene. DNA
hypomethylation is important for genome stability; then it
maycausestrandbreaksandmutagenesisthroughalterations
in chromatin conformation, which increase the accessibility
of the DNA to DNA-damaging agents promoting genomic
instability.
The activation of proto-oncogenes, such as RAS gene
and the inactivation of tumoursuppressor genes, such as theJournal of Biomedicine and Biotechnology 11
APC and TP53 have been identiﬁed in colorectal cancer.
The loss of UNC5C and DCC (deleted in colon cancer)
expression is associated with their methylation [97, 98];
aberrant methylation of these genes was detected in 68%
and 56% respectively of the primary colorectal carcinomas.
Hibi and Nakao [99] studied the combined methylation
status of P16, P14, HLFT (helicase-like transcription factor),
SOCS1 (suppressor of cytokine signalling-1), CDH13 (H-
cadherin),R U N X 3(a member of the human runt-related
transcription factor family) and CHFR (checkpoint with
FHA and RING ﬁnger) in 58 primary colorectal carcinomas
and correlated them with the pathologic features of the
patients. They found a signiﬁcant diﬀerence in histology
between the number of methylated genes and the colon
cancer stadia. Then the methylated status of colorectal carci-
nomas was signiﬁcantly correlated with malignant potential.
In a study of Ram´ ırez et al. [100], 47% of normal samples
(82 individuals) had nonmethylated gene and 41% of these
had one or two methylated-loci. Three or more methylated-
loci were observed in 12% of normal colon tissues. In
contrast, three or more methylated loci were observed in
33% of tumors samples. MGMT and P14 were the most
frequent methylated genes in CRC lesions and the least
commonly methylated in the corresponding nontumour
tissue; the hMLH1 gene, instead, was the least frequent
methylated gene in CRC tissues. Choi and co-workers
observed that the promoter region of the ADAM23 gene was
hypermethylated in colorectal cancer cell lines and tissues.
Gene silencing caused by aberrant promoter hypermethy-
lation is likely to result in abnormal cell-cell interactions
and favour cell migration and metastasis [101]. DLEC1,
located at 3p22.3, is a common tumour suppressor locus
with frequent genetic abnormalities in multiple cancers. It
was found frequently silenced by promoter methylation in
colorectal and gastric cancers in a tumour-speciﬁc manner.
Tumour-speciﬁc promoter methylation makes this gene a
biomarker for tumour early diagnosis. Reintroduction of
DLEC1 into silenced tumour cells signiﬁcantly suppressed
tumour cell clonogenicity [102]. Germline mutations in
the tumour suppressor APC cause FAP, and somatic muta-
tions are common in sporadic CRCs. Hypermethylation
of APC promoter 1A has been reported in early steps of
carcinogenesis in several tumours [103]. A study reported
that the frequencies of aberrant promoter methylation were
16% for CDH1,2 %f o rP16,4 %f o rMGMT and 24%
for APC genes. An aberrant methylation of at least one of
these genes was found in 45 of 51 (88%) primary tumors
[104]. Ras association domain family protein 1A (RASSF1A)
is a tumor suppressor protein involved in death receptor-
dependent apoptosis and it is localized to microtubules.
RASSF1A methylation levels were found signiﬁcantly higher
in distal CRCs; then methylation levels of RASSF1A and
SFRP1 in the normal-appearing mucosa of distal CRC cases
were signiﬁcantly higher than those in the proximal CRC
cases. Hypermethylation of these genes was also positively
correlated with age [105]. Silencing of SFRP by promoter
methylation causes constitutive activation of the Wnt/B-
catenin signaling patway, which is associated with several
tumors as well as CRC. Thus changes in methylation pattern
of the promoter CpG islands are very common in CRC. In a
study 31 targets have been analyzed, 65 cases of CRC, 8 cases
of adenoma, ﬁve cases of noncancerous mucosa from the
cancerpatientsandonecasemucosafromthenon-cancerous
patient.Bytakingthemethylationproﬁleofthemucosafrom
the non-cancerous patient as the reference, the following
genes MGMT, hMLH1, P16, MINT1, MINT31, COX2, cyclin
A1, CDX1, RAR-b, MYOD1, P15, CDH13, CXX1, P73,a n d
WT1 assumed altered methylation patterns [106].
4.2. Modiﬁcations of Histones in Colorectal Cancer. Another
epigenetic change is chromatin modiﬁcation, speciﬁcally,
covalent modiﬁcations of the histone proteins. Histone
acetylation is a hallmark of active regions while hypoacety-
lated histone tails are found in transcriptionally inac-
tive euchromatic or heterochromatic regions. The acety-
lation/deacetylation is performed by histone deacetylases
(HDACs) and histone acetyl transferases. Phosphorylation
of serine 10 in histone H3 has been correlated with gene
inactivation in mammalian cells; methylation of lysine
9 of histone H3 is associated with DNA silencing. The
modiﬁcations present on histone tails are recognized by
chromatin-remodelling enzymes that are able to modify
chromatin structure; chromodomain helicase DNA-binding
protein 5 (CDH5) is a tumor suppressor that is involved
in proliferation, apoptosis, and senescence. It was found
that epigenetic inactivation of CDH5 contributes to aberrant
structural changes of chromatin on genome of the cancer
cells (colon, breast, cervix, glioma) [107].
Maz´ on Pel´ aez and coworkers suggest that histone cova-
lent modiﬁcations can be aﬀected by oncogenic RAS path-
ways to regulate the expression of target genes like Cyclin
D1 or E-cadherin and that the dynamic balance of opposing
histone-modifying enzymes is critical for the regulation of
cell proliferation [108].
Responsegenetocomplement32(RGC-32)isasubstrate
and regulator of CDC2, and its overexpression induces cell
cycleactivation. The expression of RGC-32 was found higher
in advanced stages of colon cancer than in precancerous
states or the initial stages of colon cancer. RGC-32 knock-
down induced an increase in acetylation of histones H2B
lysine5(H2BK5),H2BK15,H3K9,H3K18,andH4K8.RGC-
32 silencing was also associated with decreased expression of
SIRT1anddecreasedtrimethylationofhistoneH3K27.These
datasuggestthatRGC-32maycontributetothedevelopment
of colon cancer by regulating chromatin assembly [109].
4.3. MiRNA and Colorectal Cancer. Another type of epi-
genetic event is driven by microRNAs (miRNAs), short,
non-coding RNAs, that regulate the translation of several
genes binding to their 3 UTR regions (degrading mRNA
or repressing the expression of their proteins). MiRNAs are
involved in several biological processes; a study marked a
miR-34a decrease in human colon cancer tissues compared
withnormaltissues;miR-34ainhibitedSIRT1expressionand
increased the levelofacetylated p53;suppression ofSIRT1 by
miR-34a led to apoptosis in human colon cancer cells [110].
Methylation of miR-34b/c, miR-9-1, miR-129-2 and R-13712 Journal of Biomedicine and Biotechnology
genes was observed in CRC cell lines and in primary CRC
tumour in respect to normal mucosa. Expression of K-RAS
was found inversely correlated with miR143 in vivo; miR-
143 was inversely correlated with mRNA and the protein
expression of DNMT3A in CRC. Then, miRNAs expression
could be reduced by means of DNA methylation, but also it
could downregulate expression of DNMT and inﬂuence the
expression of tumour suppressor genes. Inverse association
between the level of APC mRNA and miR135 was observed
in colorectal adenomas and carcinomas [111]. In colorec-
tal tumors miR-124a could be repressed by CpG island
hypermethylation, in respect to normal tissues; it could thus
inﬂuence the expression of oncogenic proteins which are
not normally regulated by methylation. MiRNA, as miR-29,
couldalso target DNMT3Aor 3B,participating to reduction
of DNA methylation. MiRNAs could be downregulated in
tumors, due to chromosomal mutations, normally present
in cancers. Recent studies have observed a role of miRNA
in metastasis formation. MiR-21, upregulated in colorectal
cancer,promotesinvasion andmetastasis bydownregulating
Pdcd4 [112].
4.4. Genetic and Environmental Factors Likely Aﬀecting DNA
Methylation in Colorectal Cancer
4.4.1. Polymorphisms of Folate Metabolizing Genes and DNA
Methylation in Colorectal Cancer. Folate is a fundamental
nutrient mainly required for either DNA synthesis or
methylation processes. Particularly, it is required for the
synthesis of S-adenosylmethionine (SAM) the major intra-
cellular methyl donor. The availability of SAM is directly
inﬂuenced by the diet. SAM is formed from methyl groups
derivedfrom choline, methionine, or methyltetrahydrofolate
(MTHF). Because of their involvement in DNA methy-
lation, single nucleotide polymorphisms (SNPs) in genes
involved in folate metabolism could be associated with
either aberrant gene methylation or CIMP. Indeed, several
polymorphisms of genes involved in folate metabolism,
including methylenetetrahydrofolate reductase (MTHFR)
C677T and A1298C, methionine synthase (MTR) A2756G
andmethioninesynthasereductase(MTRR)A66G;thymidy-
late synthase (TYMS) 28 bp repeats, DNA methyltransferase
(DNMT3b) -149C>T, and the transcobalamin II (TCNII)
776G variant, often in combination with folate intake, have
been associated with CRC risk, CIMP, MSI phenotypes, and
aberrant methylation of CRC genes (Table 5)[ 113–122].
4.4.2. Environmental Factors that Might Inﬂuence Epigenetic
Patterns in Colorectal Cancer. Studies where people migrate
from low to high CRC risk areas of the world, demonstrate
that changes of diet and physical activity enhance the inci-
dence of cancer in a high-risk country even over one or two
generations [123]. Moreover, monozygotic twins carriers of
high penetrant genetic alteration in HNPCC,associated with
MLH1 mutations, develop cancer at diﬀerent ages. These
observations suggest a role of the environment in epigenetic
changes [124]. Table 5 summarizes the contribution of
environmentalfactorstoepigeneticmodiﬁcationsrelevantto
CRC.
Lowlevelsoffolate in thedietorin blood were associated
with higher CRC risk; inversely high intake offolate has been
associated with reduced CRC risk [125]. It also observed
that high plasma folate levels may be associated with
increased CRC risk [126]. A study observed a small trend for
higher levels of serum folate in the group of patients with
methylated tumours, compared to those with unmethylated
tumours (P = .06); moreover it was observed a trend for
association between serum folate/vitamin B12 levels and
genepromotermethylation:higherserumfolate/vitaminB12
levels were strongly associated with promoter methylation
of P16 and had an association (trend) with promoter
methylation of MLH1 and MLH2 genes [127]. Other studies
demonstrated that high folate intake enhances colorectal
recurrence and progression. Animal studies demonstrated
thathigh-doseoffolicacidmightpromotecolorectaltumori-
genesis [128, 129]. Folate supplementation could protect
against CRC in normal colorectal tissue, instead it could
promote tumour progression in pre-existing lesions [125].
Alterations in folate metabolizing genes or deﬁciency
of folate can result in elevated homocysteine levels. Folate
deﬁciency is signiﬁcantly more associated with oncogenesis
when combined with hyper-omocysteinemia (increased risk
of 17 times of carcinogenic lesions); moreover, inﬂam-
matory bowel disease patients with folate deﬁciency and
hyperhomocysteinemia might be associated with increased
risk colorectal cancer [130]. It was observed that a positive
association between vitamin B6 and rectal cancer risk exists
in women. Among men, methionine was associated with
a decreased risk of proximal colon cancer whilst among
women it was inversely associated with rectal cancer [131].
Choline could derive from the diet, but also from
de novo biosynthesis by means of an enzyme coded
by the gene phosphatidylethanolamine-N-methyltransferase
(PEMT). One of choline metabolites, betaine, participates
in the methylation of homocysteine to form methionine.
Thencholineandbetainehavebeenhypothesized todecrease
the risk of colorectal cancer. Estrogens cause a marked up-
regulation in PMET mRNA expression and enzyme activity,
then premenopausal women have an enhanced capacity for
de novo biosynthesis of choline. In choline deﬁcient cells
in culture, and in fetal rodent brains from mothers fed
with choline-deﬁcient diets, methylation of the CDKN3
gene promoter decreased, resulting in overexpression of this
gene which inhibits cell proliferation. Maternal diet high
in choline and/or methionine and/or methyl-folate during
pregnancy results in epigenetic changes in gene expression
in the fetus [132].
Alcohol consumption was found to be a risk factor for
colorectal tumorigenesis. In an in vivo study (male rats), it
was observedthat adecrease inRFC1(reducedfolatecarrier)
mRNAandproteinexpression existsduringalcoholism.That
is a possible reason of lower blood folate levels commonly
found in chronic alcoholics [133]. Alcohol in murine studies
appears to reduce MTR levels; then it could induce DNA
hypomethylation [134]. In a Dutch study, higher frequency
of promoter methylation of APC 1A, P14, MLH1, MGMT,
and RASSF1A was observed in low-folate/high-alcohol indi-
viduals respect to high-folate/low alcohol consumers [135].Journal of Biomedicine and Biotechnology 13
Table 5: Genetics and environmental factors linked to epigenetic changes in CRC.
Genetic and environmental factors Epigenetic changes in CRC
TYMS 28 bp 3R/3R genotype Associated with CIMP−CRC
MTHFR 677TT + 1298 CC genotypes/adequate folate intake Reduced MSI CRC risk
MTHFR AC or CC genotype, low folate and methionine, high
alchol Associated with CIMP+ CRC risk
TCNII 776G variant Reduced CIMP+ CRC risk
MTHFR 677CT genotype Decreased MGMT promoter hypermethylation
MTR A2756G Reduced CIMP CRC risk, among men
MTRR A66G Reduced MLH1 methylation
DNMT -149TT Reduced risk proximal CRC (principally CIMP+ tumour)
High serum folate/vitB12 Associated with P16 promoter methylation and with MLH1, MLH2
promoter methylation(trend)
Choline deﬁciency Reduced CDKN3 promoter methylation
Low folate/High alcohol Increased APC 1A, P14, MLH1, MGMT, and RASSF1A promoter
methylation (trend)
Alchol (murine studies) Reduced MTR levels/DNA hypomethylation
Tobacco Reduced methylation levels of MGMT, RAR-b, and SST genes
Heavy smokers/lowfolate/low ﬁber intake/long-term alcohol
consumption Increased CIMP+ CRC risk (trend)
Green tea Demethylation of MLH1, MGMT, and P16 genes
Energy restriction Decreased CIMP+ CRC
Higher dietary ﬁber Reduced risk CIMP+ CRC/restore protein acetylation (p53, Sp1, Sp3)
Obesity Increased CIMP-low CRC, not CIMP high CRC
Physical activity/use NSAIDs Reduced CIMP-low and CIMP-high CRC
Tobacco could also inﬂuence CRC risk. The methylation
levels for MGMT, RAR-b,a n dSST decrease in the follow-
ing sequence: nonsmokers without colorectal adenomas >
smokers without colorectal adenomas > nonsmokers with
colorectal adenomas > smokers with colorectal adenomas.
Smoking predisposes to diminished methylation of several
genes, which, in turn, contribute to colorectal adenoma
development [136]. A study reported, although without
statistical signiﬁcance, that the risk of CIMP-high tumor,
among smokers of 20 or more cigarettes per day, was
higher among those with low folate and low ﬁber intake
and those who had greater longterm alcohol consumption.
Moreover, among women alcohol and cigarette smoking
were associated with risk of CIMP-high tumors; women who
smoked 20 or more cigarettes per day and consumed little
or no alcohol did not have an increased risk of a CIMP-high
tumors [137].
In an in vitro study on HT 29 cells, green tea inhibited
DNMT1 causing CpG demethylation and reactivation of
previously methylated genes (hMLH1, MGMT, P16). Also
seleniumsuppressed aberrant DNAmethylation by means of
DNMT inhibition [134].
Energy restriction during adolescence and early adult-
hood is associated with the CIMP phenotype in CRC, sug-
gesting that exposure to a transient environmental condition
during this period of life may result in persistent epigenetic
changes that later inﬂuence CRC development. Individuals
exposed to a period of severe short-term energy restriction,
had a decreased risk of developing a CIMP tumor later
in life respect to individuals who were not exposed. The
prepubertal and pubertal years are a period of rapid growth
and hormonal change, where insulin-like growth factor-1
(IGF-1) can be four-times the normal adult serum concen-
tration. IGF-1 inhibitsapoptosis and stimulates proliferation
of colonic epithelial cells in vitro. High levels of IGF-1 have
been associated with a signiﬁcant increase in colon cancer
risk [138].It couldbepossible thatenergy restriction, during
puberty, may permanently inﬂuence the growth hormone-
IGFaxis, subsequentlyinﬂuencingmethylation patterns later
in life [139].
Fiber intake reduces CRC risk, with dilution of fecal
potential carcinogens, promoting a favorable colonic micro-
ﬂora, by adsorption of bile acids and by production
of protective short-chain fatty acids (SCFAs principally
acetate, propionate, and butyrate) through fermentation by
endosymbiotic bacteria. Butyrate is a potent inhibitor of
histone deacetylases (HDACs); reduced levels of butyrate
will cause alterations in global protein acetylation, which
may be permissive for colorectal cancer progression, while
elevation of ﬁbre levels and consequent butyrate levels may
reduce or reverse these processes and restore a “normal”
proﬁle of protein acetylation. Acetyl proteins identiﬁed are
nuclear structural proteins, transcription factors including
p53, Sp1, and Sp3, and structural proteins including tubulin
and cytokeratins [140]. Higher dietary ﬁber was associated
withreducedriskofhavingaCIMP-high tumor[137].Obese14 Journal of Biomedicine and Biotechnology
individuals were at 2-fold increased risk of CIMP-low colon
cancer, but obesity does not inﬂuence CIMP-high tumors
[137].
DNA methylation has been also hypothesized as being a
consequence of inﬂammation. Prostaglandins, that promote
inﬂammation and fever, are produced within the body
cells by the enzyme cyclooxygenase (COX). Nonsteroidal
antiinﬂammatory drugs (NSAIDs) block the COX enzymes
and reduce prostaglandins throughout the body, then their
assumption has been hypothesized to be associated with
development of colon tumors that display CIMP.
Physical activity and use of NSAIDs were inversely
associated withbothCIMP-low and CIMP-high tumors. The
protective eﬀect associated with regular NSAIDs use largely
disappeared among heavy smokers [137].
5.ConcludingRemarks
An unresolved question related to genomic instability, which
has been raised in many papers, is whether CIN arises
early in tumorigenesis and initiates the adenoma-carcinoma
sequence or whether it is acquired during this process and
facilitates the formation of colon cancer. According to the
genetic model of colorectal tumorigenesis, cancers develop
over the course of 20–40 years due to genetic disruption of
the APC, RAS, and p53 pathways. Genetic instability arises
somewhere during the process of colorectal tumorigenesis,
but whether it is the ﬁrst event and therefore, initiates and
drives the neoplastic transformation is still a matter of much
debate [141].
Some reports suggest that CIN arises early in colorectal
tumorigenesis and, subsequently, drives tumor progression.
Michor et al. [141] developeda mathematical representation
oftheevolutionarydynamicsofcolorectaltumorigenesisand
found that one or two CIN genes in the genome are enough
to make sure CIN emerges early.
However this view is not universally accepted: some
Authors are inclined to believe that CIN is acquired during
tumorigenesis and facilitates progression to malignancy.
Even in light of the latest knowledge, the question is still
considered unresolved (see the recent review by Pino and
Chung [81]).
Diﬀerent tumors show various patterns of aneuploidy.
However, since chromosomal changes found in the tumors
of diﬀerent individuals are not random, aneuploidy should
notbeconsideredasideeﬀect.Thelossofheterozigosytythat
occurin the ﬁrst phases ofthe CRCcancerogenesis, as well as
the alteration of methylation pattern of multiple key genes
can drive the developmentof colorectal cancer by facilitating
the acquisition of multiple tumor-associated mutations and
the instability phenotype.
Aberrant CpG island methylation is involved in cancer
development, but it is not yet clear if it is a cause or an eﬀect
of cancer formation, which genes are methylated during
the pathogenesis of individual cancers, when is the time of
methylation and gene silencing, how speciﬁc methylation
proﬁles are established, and what determines tumor type-
speciﬁc methylation [103].
A restricted folate diet or SNPs in one-carbon metab-
olism, then the reduction of the total amounts of DNA
methylation in human tumors leads to hypomethylation
of repetitive DNA sequences, contributing to the origin
of cancer cells by generation of chromosomal instability,
reactivation oftransposableelements,andlossofimprinting;
moreover, hypomethylation could activate proto-oncogenes.
The misincorporation of uracil into human DNA, favoured
when thymidylate availability is restricted, could also
increase the frequency of chromosome cleavage. On the
other hand, tumor suppressor genes could gain CpG island
methylation, resulting in the inactivation of these protecting
proteins. Moreover epigenetic alterations could inﬂuence
either cancer initiation or progression. A tumor could
take diﬀerent paths; therefore it is important to obtain
data about age, sex, tumor site, stadiation, and diet when
investigating genetic and epigenetic risk factors for CRC.
DNA methylation and histone modiﬁcation changes are
reversible, while genetic mutations are not; then, it could
be interesting to evaluate their relationship with dietary
factors and the geneticbackgroundof theindividuals, for the
development of novel strategies for cancer prevention.
There is a need for a preventive strategy that can utilize
biomarkers in order to stratify patients into appropriate
screening or surveillance programs. In CRC, the best
biomarkers are germline APC mutations, which are highly
predictive of colon cancer. Moreover, CRC in particular
has a potential for prevention, since most cancers follow
the adenoma-carcinoma sequence, and the interval between
detection of an adenoma and its progression to carcinoma is
usually about a decade.There is also need of identifying clin-
icalvariables (biomarkers)associated withclinicaloutcomes.
New molecular biomarkers may be identiﬁed in the next
decade, such as epigenetic methylation patterns and genetic
polymorphisms.
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